Navigation Links
Tokai Pharmaceuticals' galeterone well-tolerated in patients with advanced prostate cancer
Date:3/31/2012

gy at the University of Washington School of Medicine, and their colleagues at leading prostate cancer research centers in the United States. The Phase 1 proof-of-concept clinical trial, part of the ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program for the evaluation of galeterone, enrolled 49 patients and was a dose-finding study to evaluate escalating dose levels of galeterone. The study also evaluated safety and reduction in prostate-specific antigen (PSA) levels from baseline levels measured at first visit. Patients who responded to therapy had the option to continue treatment with galeterone in an extension arm of the trial.

Most side effects were minor and included fatigue, nausea and diarrhea. Early efficacy tests demonstrated that 49 percent of patients had prostate-specific antigen (PSA) reductions of 30 percent or more; 11 of these patients had reductions of 50 percent or more. In addition, CT scans revealed a significant reduction in tumor size for some patients.

"We are pleased with the results of our Phase 1 proof-of-concept study, which demonstrated galeterone tolerability and efficacy in a difficult-to-treat, resistant prostate cancer patient population," said Martin D. Williams, president and chief executive officer, Tokai Pharmaceuticals. "Galeterone is the only prostate cancer therapy in development that combines three distinct mechanisms of action in one compound for a unique multi-target approach. The reductions in PSA levels seen in nearly half of all patients evaluated in our Phase 1 study are meaningful in a dose-escalation study and supportive of our Phase 2 clinical trial set to initiate later this year."

In the Phase 1 study, researchers observed transient, non-serious elevated liver function tests in 15 patients, most of whom were asymptomatic. Eleven of these patients stopped galeterone treatment, and of those, six of seven patients were rechallenged and successfully ret
'/>"/>

Contact: Caton Lovett
caton@purecommunicationsinc.com
910-232-7166
Pure Communications Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
2. 2012 Biotechnology and Pharmaceuticals: Forthcoming Conferences and Exhibitions
3. Study finds an increase of children accidentally poisoned with pharmaceuticals
4. Study Shows Sutro Biopharmas Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals
5. PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
6. Environmental risk assessment of pharmaceuticals inadequate
7. Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
8. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
9. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
10. NIH awards $8.5 million for research on pharmaceuticals for children
11. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
(Date:7/11/2014)... USC Stem Cell scientists have set a "mouse TRAP" ... described by a recent study published in the ... line uses a technique called TRAP to extract cellular ... , Invented by scientists at the Rockefeller Institute for ... tag to the protein-making machinery, or ribosomes, of the ...
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... Particle Whisperers , G. Volpe, S. Perrone, J. M. Rubi, ... As many parents know, it,s often easier to keep your ... A child who fidgets uncontrollably in a confining booster seat, ... chair. A team of physicists at the Universitat de Barcelona ...
... bubonic plague may be more virulent than their close relatives ... in the May issue of the journal Microbiology. The ... at body temperature. When there is no calcium available, it ... acid, said Professor Brubaker from the University of Chicago, USA. ...
... health organisations around the world. The worry is the potential ... develop the ability to infect humans easily. New drugs and ... needed. Now one of the tactics used by influenza virus ... laid bare by structural biologists at the European Molecular Biology ...
Cached Biology News:A gentle touch for better control, a quantum mechanical con, and milestone PRL papers 2A gentle touch for better control, a quantum mechanical con, and milestone PRL papers 3A gentle touch for better control, a quantum mechanical con, and milestone PRL papers 4Getting wise to the influenza virus' tricks 2
(Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
(Date:7/10/2014)... Toronto, Canada (PRWEB) July 10, 2014 ... often present in very low abundance and are ... quite challenging and time-consuming. , Join presenters Dr. ... Laboratories, and Dr. John Anders, Head of Quality ... mass spectrometer-based approach that can speed detection and ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... and focus on mission, CHICAGO, Feb. 25 ... Foundation as its expected provider of,clinical services for ... research center to be built in the DuPage ... The announcement came as Northern Illinois University ...
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... year-end financial results on Monday, Mar. 3,2008. SuperGen ... and provide financial guidance for fiscal year-end 2008., ...
... (Nasdaq: IDIX ), a biopharmaceutical company engaged,in the ... human viral,and other infectious diseases, announced today that three ... Meeting of the European,Association for the Study of the ... - 27, 2008. Full abstracts can now be viewed ...
Cached Biology Technology:NIU Seeks OK for New Proton Cancer Treatment and Research Center 2NIU Seeks OK for New Proton Cancer Treatment and Research Center 3SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008 2Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) 2Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) 3
... CTI Molecular Imaging's proprietary Focus™ detector ... and a large imaging volume that ... image multiple mice or large primateswithout ... dedicated small animal PET (Positron Emission ...
...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
...
Biology Products: